Blueprint Medicines (BPMC) – Company Press Releases
-
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
-
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
-
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
-
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis
-
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit
-
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines Reports Third Quarter 2023 Results
-
Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board
-
Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines Reports Second Quarter 2023 Results
-
Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting
-
NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis
-
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines Reports First Quarter 2023 Results
-
Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting
-
Blueprint Medicines to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
-
Blueprint Medicines to Present at Upcoming Investor Conferences
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
-
Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche
-
Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results
-
Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222
-
Blueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
-
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
-
Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors
-
Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at Scale
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis
Back to BPMC Stock Lookup
